Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients

Maiolino, Ângelo; Costa, Luciano J.; Pasquini, Marcelo C.; Crusoé, Edvan; Vigorito, Afonso Celso; Salvino, Marco Aurélio; Seguro, Fernanda Salles; Filho, Jayr Schmidt; Hungria, Vânia

doi:10.1016/j.htct.2021.09.004

Cited by 2 publications

(2 citation statements)

References 19 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 5 Access to tocilizumab along with adequately trained ICU specialists are important requirements. 28 The American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading scale grades CRS on a scale of 1–4 based on fever, hypoxia and hypotension. 29 The ASTCT ICANS grading scale incorporates the Immune Effector Cell-associated Encephalopathy (ICE) score with level of consciousness, presence of seizure, motor findings and elevated intracranial pressure/cerebral edema to grade ICANS on a scale of 1–4.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

Hungria

Piérola

Filho

et al. 2023

Hematology, Transfusion and Cell Therapy

Self Cite

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

“… 5 Access to tocilizumab along with adequately trained ICU specialists are important requirements. 28 …”

Section: Resultsmentioning

confidence: 99%

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

Hungria

Piérola

Filho

et al. 2023

Hematology, Transfusion and Cell Therapy

Self Cite

View full text Add to dashboard Cite

CAR T-cell therapy and the onco-nephrologist

Salvino,

Mussetti,

Peña

et al. 2024

Front. Nephrol.

View full text Add to dashboard Cite

Cell therapy, specifically the revolutionary chimeric antigen receptor (CAR) T-cell therapy, has transformed the landscape of oncology, making substantial strides in practical treatment approaches. Today, established guidelines for diseases such as lymphomas, myelomas, and leukemias actively advocate the utilization of these once-unconventional therapies. The practical impact of these therapies is underscored by their unparalleled efficacy, reshaping the way we approach and implement treatments in the realm of oncology. However, CAR T-cell therapy, with its performance in anti-tumor aggression through cellular action and inflammatory response, also comes with various adverse events, one of which is kidney injury. Therefore, the management of these side effects is extremely important. The integration of knowledge between oncologists and specialized nephrologists has led to the emergence of a new sub-area of expertise for onco-nephrologists specializing in managing kidney complications from immune effector therapies.

show abstract

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients

Cited by 2 publications

References 19 publications

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

CAR T-cell therapy and the onco-nephrologist

Contact Info

Product

Resources

About